The Alzheimer's Assocation is excited to share that for our meeting TODAY, we have invited Dr. Yongku Cho, a professor at Storrs in the Department of Chemical and Biomolecular Engineering who does some pioneering research on Alzheimer's Disease (one of the only labs at Storrs that has this focus).
Please RSVP here if you're interested in attending. It should be very interesting and informative, and you may find a research connection as well!
Details:
Wednesday, 3/23, 6-7pm, in SU 325 (with time for questions at the end)
Title of presentation: Antibody therapy and biomarker detection in Alzheimer’s disease
Abstract:
In 2021, an antibody targeting beta-amyloid was approved by the US Food and Drug Administration as a treatment for Alzheimer’s disease (AD). This is the first drug to be approved for treating AD. Many other antibody drugs are under clinical trial, including those that target the human microtubule binding protein tau, which is also associated with AD. Along with the development of antibody therapeutics, AD biomarker research is making great progress. The ability to measure tau levels in clinical samples is transforming the detection of AD and other neurodegenerative diseases. In particular, accurate detection of low levels of phosphorylated tau (p-tau) in plasma provides a reliable biomarker of AD long before sensing memory less. Therefore, the diagnosis of AD and monitoring its progression using blood samples is becoming a reality. These major advances were achieved by using antibodies specific to tau as well as sophisticated high sensitivity immunoassay platforms. This presentation will focus on these enabling advances in antibody development and engineering. I will provide an overview of recent developments in this area and showcase the progress made in my laboratory.
For more information, contact: UConn Alzheimer's Association at uconnalzassoc@gmail.com